Company Filing History:
3 out of 238 
3 out of 6 
2 out of 155 
Years Active: 1996-1999
Title: Achim Wenzel: Innovator in Antibody Research
Introduction
Achim Wenzel is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of antibody research, holding a total of 3 patents. His work primarily focuses on the development of antibodies that target specific surface proteins, which has implications in cancer research and treatment.
Latest Patents
Wenzel's latest patents include innovative antibodies that react with variant CD44 surface proteins. One of his key inventions relates to antibodies that interact with a variant epitope in the extracellular region of a variant CD44 polypeptide. This variant epitope has a specific amino acid sequence that is crucial for identifying and isolating these antibodies. Additionally, he has developed a monoclonal antibody (MAb1.1ASML) that targets a surface glycoprotein of the metastasizing rat pancreatic carcinoma cell line BSp73ASML. This work has led to the identification of a complementary DNA (cDNA) clone that encodes a glycoprotein with partial homology to CD44, which is significant for understanding metastatic behavior in cancer.
Career Highlights
Throughout his career, Achim Wenzel has worked with esteemed organizations such as the Kernforschungszentrum Karlsruhe GmbH and the Universität Karlsruhe. His research has contributed to advancements in understanding the mechanisms of cancer metastasis and the role of glycoproteins in this process.
Collaborations
Wenzel has collaborated with notable scientists in his field, including Peter Herrlich and Helmut Ponta. These collaborations have further enriched his research and have led to significant findings in antibody development.
Conclusion
Achim Wenzel's innovative work in antibody research has made a lasting impact on the scientific community. His patents and collaborations continue to pave the way for advancements in cancer treatment and understanding.